Zacks Investment Research
07 Oct 2026, 19:31 UTC · 1h ago
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
Impact · against what's priced in
Reblozyl continues to show strong growth, with H1 2026 sales reaching $1.3 billion, providing a positive buffer against BMY's legacy drug declines. While the growth is robust, the key catalysts remain the upcoming FDA target date in March 2027 and long-term data expected in 2028.
- BMY+0.30
No priced-in read yet
- In context
Reblozyl sales grew 23% year-over-year to nearly $1.3 billion in the first half of 2026, establishing it as a primary driver to offset declines in legacy drug sales.
Read from the article alone
Search tags
